Clinical Trials · NCT07163624
UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
- Phase
- Phase 2
- Recruitment status
- Completed
- Sponsor
- The United Bio-Technology (Hengqin) Co., Ltd.
- Enrollment
- 211
- Start date
- Mar 2025
- Locations
- 1 site, China
- Primary endpoint
- Change From Baseline in HbA1c at Week 24